FindTrial
Sign In

COMPARISON OF EFFICACY AND SAFETY OF 2% , SODIUM FUSIDATE VERSUS 2%, MUPIROCIN CREAM VERSUS 1%,OZENOXACIN CREAM AGAINST SKIN AND SOFT TISSUE INFECTION

Comparison of efficacy of 2%, sodium fusidate cream versus 2% mupirocin cream versus 1%,ozenoxacin cream against skin and soft tissue infection-a randomised observer blinded study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/09/045863
Enrollment
135
Registered
2022-09-26
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L00-L99- Diseases of the skin and subcutaneous tissue

Interventions

Intervention1: COMPARISON OF EFFICACY OF 2% , SODIUM FUSIDATE VERSUS 2%, MUPIROCIN CREAM VERSUS 1%,OZENOXACIN CREAM AGAINST SKIN AND SOFT TISSUE INFECTION - A RANDOMISED OBSERVER BLINDED NON I

Sponsors

SIKSHA O ANUSANDHAN university
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1-No more than 10 discrete lesions, not exceeding 100 cm2 in total area , or no more than 2% of the total body surface area . 2-All patients above 2 months of age and below 65 yrs of age 3- Skin infection rating scale total score(SIRS) of at least 8.

Exclusion criteria

Exclusion criteria: . Pregnancy and lactation 2. Signs and symptoms of systemic infections 3.Extensive cellulitis, furunculosis, abscess requiring systemic therapy 5- Immunosuppressed patients. 4- Previous hypersensitivity to any component of either cream , had received a systemic antibacterial or steroid or had applied any topical therapeutic agent directly to skin lesions within the 7 days prior to study entry.

Design outcomes

Primary

MeasureTime frame
CLINICAL CLEARANCE , SKIN INFECTION RATING SCALE (SIRS) cream and sodium fusidate cream in the treatment of Skin infection rating scale, ( Parameter of SIRS- erythema, pus, crusting, pain, itching) .Assessment will be done at baseline and at the end of therapy and follow up at 14 days from the start of the therapy Timepoint: EVALUATION TO BE DONE AT 5 DAYS AND 14 DAYS FROM START OF THERAPY—

Secondary

MeasureTime frame
safety profileTimepoint: In terms of side-effects of drug at 7 day and 14 day from the start of treament—

Countries

India

Contacts

Public ContactDr Nibedita Dixit

Ims and Sum Hospital

nibeditadixit@soa.ac.in8249855790

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026